Fennec Pharmaceuticals (FRX) Stock Statistics & Valuation Metrics

Fennec Pharmaceuticals has a market cap or net worth of C$312.92M. The enterprise value is ―.

Fennec Pharmaceuticals has 27,618,744 shares outstanding. The number of shares has decreased by -2.65% in one year.

Fennec Pharmaceuticals’s return on equity (ROE) is 1.38 and return on invested capital (ROIC) is -66.06%.

The current PE Ratio of Fennec Pharmaceuticals is -18.93. Fennec Pharmaceuticals’s PEG ratio is -1.61.

In the last 12 months, Fennec Pharmaceuticals had revenue of 21.25M and earned -16.05M in profits. Earnings per share was -0.60.

In the last 12 months, operating cash flow was 26.98M and capital expenditures 0.00, giving a free cash flow of 26.98M billion.

Fennec Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Fennec Pharmaceuticals upcoming earnings date is Aug 7, 2025, TBA Not Confirmed.

Fennec Pharmaceuticals as a current ratio of 3.56, with Debt / Equity ratio of -329.36%

In the past 12 months, Fennec Pharmaceuticals has paid 0.00 in taxes.

Fennec Pharmaceuticals EV to EBITDA ratio is -26.00, with an EV/FCF ratio of -18.75.

Fennec Pharmaceuticals has C$26.63M in cash and marketable securities with $19.34M in debt, giving a net cash position of -C$7.29M billion.

Gross margin is 93.30%, with operating margin of -60.09%, and net profit margin of -75.50%.

The average price target for Fennec Pharmaceuticals is C$18.72, which is 11.43% higher than the current price. The consensus rating is Strong Buy